As part of the planning committee, I’m very pleased to share this year’s theme for the 2018 ISPE Quality Manufacturing Conference, June 4-6 in Arlington, VA: Manufacturing and Quality: Present and Future Opportunities to Ensure Continuous Improvement; and we have put together three very interesting and timely tracks on Regulatory, Quality and Manufacturing, and Facilities and Equipment topics.
One session that I am very excited about is the one centered on Contamination Control Strategies. The session will include perspectives from experts in the pharma industry and the U.S. FDA; and will delve into Contamination Control Strategies for sterile and non-sterile manufacturers as an essential consideration for preventing product contamination. Pharma industry experts will share successful ways to communicate and manage contamination controls, with real-life examples.
Attendees will also have a chance to participate in a Q&A session that poses questions such as:
I am really looking forward to attending this session as part of the 2018 ISPE Quality Manufacturing Conference and hope that you will join me in June.
Best Regards
The ISPE Quality Manufacturing Conference is the foremost pharmaceutical quality event of the year. It provides a unique forum for attendees and speakers from industry, academia, and regulatory to address areas for opportunities to assure innovation and continuous supply of high-quality products to our patients.
Here’s what you can expect:
Register by Monday, 26 March to take advantage of our lowest rates — saving you $400 or more!
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...